Ceftriaxone

C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

$/$$

Dosing

Usual Dose 1-2 gm IV q24h

Bacterial meningitis 2 gm IV q12h

CrCl >50 mL/min

  • Uncomplicated: 1 g IV Q24h

  • Meningitis: 2 g IV Q12h

  • Endocarditis & Osteomyelitis: 2 g IV Q24hCrCl <50 mL/min

  • No change

Creatinine Clearance >50mL/min/1.73m²Creatinine Clearance 10-50mL/min/1.73m²Creatinine Clearance ≤10mL/min/1.73m²50-75mg/kg/dose Q24H
Maximum: 1g/doseNo changeNo change

Creatinine Clearance >50mL/min/1.73m²Creatinine Clearance 10-50mL/min/1.73m²Creatinine Clearance ≤10mL/min/1.73m²50mg/kg/dose Q12H
Maximum: 2g/doseNo changeNo change

Creatinine Clearance >50mL/min/1.73m²Creatinine Clearance 10-50mL/min/1.73m²Creatinine Clearance ≤10mL/min/1.73m²50mg/kg/dose Q12H
Maximum: 2g/doseNo changeNo change

General Information

  • GI effects

  • Hypersensitivity reactions

  • C. difficile

  • Biliary sludging

  • Gallstones

Laboratory

  • CBC, CMP weekly

  • Consider more frequent liver enzymes in patients with biliary disease

Clinical

  • Hypersensitivity

  • Diarrhea

  • Other GI effects

  • Signs of biliary sludge

  • Signs of gallstones

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Empiric therapy of bacterial meningitis

Empiric therapy of nosocomial Gram negative infections (except Pseudomonas)

Empiric therapy of hospitalized community or nursing home acquired pneumonia in combination with a macrolide

Empiric therapy of spontaneous bacterial peritonitis